Evidence map›Paper›PMID 34988689›Full record

ArticleJournal of gastroenterology2022

T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production.

Yong Liu, Xintong Hu, Xiaoli Hu, Lei Yu, Huifan Ji, Wanyu Li, Yanjun Cai, Genhong Cheng, Yanfang Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. [Research progress on B cells in chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Immune Checkpoint Molecules Expressed on CD4Frontiers in microbiology · 2022
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Yong Liu *Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, 130021, China.
Xintong Hu *Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, 130021, China.
Xiaoli HuDepartment of Infectious Disease, Heilongjiang Provincial Hospital, Harbin, China.
Lei YuDepartment of Infectious Disease, The Fourth Hospital of Harbin Medical University, Harbin, China.
Huifan JiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Wanyu LiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Yanjun CaiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Genhong ChengKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, 130021, China.
Yanfang JiangKey Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, 130021, China. yanfangjiang@hotmail.com.ORCID 0000-0002-2478-1521
Jilin University · CNHarbin Medical University · CNUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatitis B surface antigen (HBsAg) seroconversion is considered the optimal outcome of the treatment of chronic hepatitis B virus (HBV) infection. In this study, we aimed to determine the cellular and molecular mechanisms by which pegylated interferon alpha (PEG-IFN-α) improves the seroconversion rate in patients with chronic hepatitis B (CHB).

methodsFlow cytometry was performed using circulating T follicular helper (TFH) cells from 15 healthy individuals and 45 patients with CHB presenting different treatment responses [complete response group (CRG), incomplete response group (ICRG), and nonresponse group (NRG)] to the standard 48-week regimen of PEG-IFN-α monotherapy to examine the significance of circulating TFH cells in the therapeutic response of patients with CHB to PEG-IFN-α. In addition, the capacities of different TFH subsets to activate B cells and stimulate IgG production were assessed by performing coculture experiments.

resultsLongitudinal analysis revealed specific and significant increases in the numbers of CD40L

conclusionsTFH cells, particularly those with CD40L expression, stimulate B-cell differentiation and improve the HBsAg seroconversion rate in patients with CHB treated with PEG-IFN-α monotherapy.

Indexed as

Hepatitis B, ChronicT Follicular Helper CellsAntiviral AgentsHepatitis B Surface AntigensHepatitis B virusHumansInterferon-alphaT-Lymphocytes, Helper-InducerAntiviral AgentsHepatitis B Surface AntigensInterferon-alphaChronic hepatitis BHBsAbInterferon-αRegulatory T cellsT follicular helper cells

Identifiers

PMID34988689
OpenAlexW4206223806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.